In the SURMOUNT-1 study, a phase 3 clinical trial in obese patients, randomized participants in a 1:1:1:1 ratio to tirzepatide (5, 10, 15 mg) or placebo over 72 weeks, significant weight reductions were observed at 72 weeks: 15.0% for 5 mg, 19.5% for 10 mg, 20.9% for 15 mg, compared to 3.1% for placebo [18]
[1] [2] Whilst this medication offers significant benefits in glycaemic control and weight management, patients commonly report gastrointestinal side effects during treatment
Ive watched patients regain hope and energy as the pounds come offoften for the first time in years
The study is important because it confirms that GLP-1RA therapy has clinically meaningful systemic effects, reinforcing the need to understand how metabolic benefit is integrated with broader nutritional and physiological adaptation
So, we're adding to that
As its use expands across the UK, discussions around Wegovy and blood clots are becoming more common, though often without full clinical context
